NasdaqGS:MBXPharmaceuticals
Evaluating MBX Biosciences (MBX) Valuation After MBX 2109 Phase 2 Progress And Stronger Investor Sentiment
MBX Biosciences (MBX) is drawing attention after progress updates on its lead therapy MBX 2109 in Phase 2 trials for chronic hypoparathyroidism and early pipeline candidates in other metabolic indications, along with stronger recent investor interest.
See our latest analysis for MBX Biosciences.
At a recent share price of $36.75, MBX Biosciences has paired a 5.63% 1 day share price return and 16.30% 90 day share price return with a 1 year total shareholder return of about 3.5x. This suggests...